citalopram has been researched along with Chronic Disease in 71 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression." | 9.22 | Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016) |
| "Escitalopram has never been demonstrated to be useful in the treatment of chronic low back pain (CLBP), while duloxetine has demonstrated analgesic effect in chronic pain states." | 9.14 | Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. ( Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C, 2010) |
| "Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included." | 9.13 | Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008) |
| "To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability." | 9.13 | Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008) |
| "The tricyclic antidepressant amitriptyline is the only documented and most widely used prophylactic drug for chronic tension-type headache (CTTH)." | 9.11 | Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. ( Ashina, S; Bendtsen, L; Jensen, R, 2004) |
| "In design 1, fatigue for subjects taking citalopram was significantly and substantially reduced when subjects were switched from placebo to citalopram, p <." | 9.10 | The effectiveness of citalopram for idiopathic chronic fatigue. ( Bentler, SE; Brake, KA; Hartz, AJ; Kelly, MW, 2003) |
| " The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)." | 9.08 | Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997) |
| "Although the tricyclic antidepressant amitriptyline is extensively used in the prophylactic treatment of chronic tension-type headache, only few studies have investigated the efficacy of this treatment and the results are contradictory." | 9.08 | A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R; Olesen, J, 1996) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 7.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| " This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram." | 7.77 | Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. ( Liu, X; Mullins, CD; Wang, J, 2011) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 7.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| "The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression." | 7.70 | The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000) |
| "Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia." | 6.75 | Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010) |
| "Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms." | 5.30 | Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999) |
| "To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression." | 5.22 | Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016) |
| "Escitalopram has never been demonstrated to be useful in the treatment of chronic low back pain (CLBP), while duloxetine has demonstrated analgesic effect in chronic pain states." | 5.14 | Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. ( Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C, 2010) |
| "Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included." | 5.13 | Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008) |
| "To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability." | 5.13 | Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008) |
| "The tricyclic antidepressant amitriptyline is the only documented and most widely used prophylactic drug for chronic tension-type headache (CTTH)." | 5.11 | Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. ( Ashina, S; Bendtsen, L; Jensen, R, 2004) |
| "In design 1, fatigue for subjects taking citalopram was significantly and substantially reduced when subjects were switched from placebo to citalopram, p <." | 5.10 | The effectiveness of citalopram for idiopathic chronic fatigue. ( Bentler, SE; Brake, KA; Hartz, AJ; Kelly, MW, 2003) |
| " The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)." | 5.08 | Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997) |
| "Although the tricyclic antidepressant amitriptyline is extensively used in the prophylactic treatment of chronic tension-type headache, only few studies have investigated the efficacy of this treatment and the results are contradictory." | 5.08 | A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R; Olesen, J, 1996) |
| "Data of 1296 outpatients with nonpsychotic depression who entered a 12-month naturalistic follow-up period after achieving remission with citalopram for up to 14 weeks were analyzed." | 4.31 | Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data. ( Kubo, K; Mimura, M; Sakurai, H; Tani, H; Uchida, H; Watanabe, K, 2023) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 3.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| " This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram." | 3.77 | Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. ( Liu, X; Mullins, CD; Wang, J, 2011) |
| "The purpose of this study was to analyze the antidepressant-like actions of estradiol valerate (1 or 2 mg/rat, single injection) or citalopram (5 or 10 mg/kg, chronically administered for 21 days) given independently or combined at low doses, to middle-aged ovariectomized female rats, as a model of human menopause." | 3.76 | Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. ( Fernández-Guasti, A; Romano-Torres, M, 2010) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| "A stress-induced decrease in sucrose preference in rodents is regarded as an analog of anhedonia, a key symptom of depression." | 3.73 | Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. ( Bartsch, D; Dolgov, O; Gorenkova, N; Schunk, E; Strekalova, T, 2006) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 3.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression." | 3.70 | The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000) |
| " Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, is required to elicit significant benefit of these agents on lower limb function poststroke." | 2.80 | Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke. ( Gourab, K; Hornby, TG; Schmit, BD, 2015) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Despite a substantial improvement in PTSD symptoms, there was virtually no change in BDNF levels over time." | 2.75 | Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. ( Berger, W; Lenoci, M; Marmar, CR; Mehra, A; Mellon, SH; Metzler, TJ; Neylan, TC; Otte, C; Tarasovsky, G; Wolkowitz, OM, 2010) |
| "Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia." | 2.75 | Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | 2.73 | A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| "Methylphenidate was tapered and discontinued during weeks 9 and 10." | 2.71 | Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. ( Kim, MD; Kumar, A; Lavretsky, H; Reynolds, CF, 2003) |
| "Baseline measures of PTSD, depression, salivary 8 am and 4 pm cortisol, and serum interleukin-1beta (IL-1beta; pro-inflammatory) and soluble interleukin-2 receptors (IL-2R; cell-mediated immunity) were obtained for 58 PTSD and 21 control subjects." | 2.71 | Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. ( Hossain, A; Masters, B; Parker, DE; Ruwe, WD; Trautman, RP; Tucker, P; Wyatt, DB, 2004) |
| "All of the patients with primary conversion disorder had a current or previous depressive or anxiety disorder compared with 40% (N = 2) of the patients with additional somatoform diagnoses." | 2.71 | Antidepressant treatment outcomes of psychogenic movement disorder. ( Lang, AE; Voon, V, 2005) |
| "Escitalopram has previously been shown to be effective and well tolerated in the acute treatment of GAD." | 2.71 | Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. ( Bose, A; Davidson, JR; Wang, Q, 2005) |
| " Citalopram dosing began at 20 mg/day and could be titrated to 60 mg/day." | 2.70 | Naturalistic study of the early psychiatric use of citalopram in the United States. ( Bose, A; Heydorn, WE; Rush, AJ, 2002) |
| " Chronic administration of amitriptyline reversed the despaired behavior induced by exposure to UCMS paradigm and, fully recovered pNF-H labeling to control values." | 1.46 | Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. ( Galeotti, N; Ghelardini, C; Sanna, MD, 2017) |
| "Escitalopram treatment significantly decreased PAI-1 levels in the serum, but not in the CSF." | 1.43 | Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies. ( Chen, S; Jiang, H; Li, X; Liang, J; Lu, N; Yuan, Y; Yue, Y; Zhang, Z, 2016) |
| "Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours." | 1.40 | Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. ( Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014) |
| "Escitalopram was associated with higher expected number of SFDs than paroxetine (86." | 1.35 | Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. ( Bereza, BG; Einarson, TR; Iskedjian, M; Le Melledo, JM; Walker, JH, 2008) |
| "Escitalopram (ES-CIT) is a widely used, highly specific antidepressant." | 1.35 | Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. ( Abumaria, N; Danker-Hopfe, H; Fuchs, E; Hellweg, R; Hiemke, C; Schulte-Herbrüggen, O; Ziegler, A, 2009) |
| "Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6." | 1.35 | Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. ( Alpert, JE; Fava, M; Fleck, J; Gilmer, WS; Gollan, JK; Howland, RH; Miyahara, S; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2008) |
| "Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms." | 1.30 | Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.41) | 18.7374 |
| 1990's | 5 (7.04) | 18.2507 |
| 2000's | 33 (46.48) | 29.6817 |
| 2010's | 30 (42.25) | 24.3611 |
| 2020's | 2 (2.82) | 2.80 |
| Authors | Studies |
|---|---|
| Kubo, K | 1 |
| Sakurai, H | 1 |
| Tani, H | 1 |
| Watanabe, K | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Wigner, P | 1 |
| Synowiec, E | 1 |
| Jóźwiak, P | 1 |
| Czarny, P | 1 |
| Bijak, M | 1 |
| Białek, K | 1 |
| Szemraj, J | 1 |
| Gruca, P | 2 |
| Papp, M | 4 |
| Śliwiński, T | 1 |
| Bausch, P | 1 |
| Fangmeier, T | 2 |
| Zobel, I | 2 |
| Schoepf, D | 2 |
| Drost, S | 2 |
| Schnell, K | 2 |
| Walter, H | 2 |
| Berger, M | 2 |
| Normann, C | 2 |
| Schramm, E | 2 |
| Wu, C | 1 |
| Gong, WG | 2 |
| Wang, YJ | 1 |
| Sun, JJ | 1 |
| Zhou, H | 1 |
| Zhang, ZJ | 3 |
| Ren, QG | 1 |
| Zhong, Q | 1 |
| Yu, H | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| Wang, H | 1 |
| Xu, J | 1 |
| Cheng, Y | 1 |
| do Prado-Lima, PAS | 1 |
| Onsten, GA | 1 |
| de Oliveira, GN | 1 |
| Brito, GC | 1 |
| Ghilardi, IM | 1 |
| de Souza, EV | 1 |
| Dos Santos, PG | 1 |
| Salamoni, SD | 1 |
| Machado, DC | 1 |
| Duarte, MMF | 1 |
| Barbisan, F | 1 |
| da Cruz, IBM | 1 |
| Costa-Ferro, ZSM | 1 |
| daCosta, JC | 1 |
| Opal, MD | 1 |
| Klenotich, SC | 1 |
| Morais, M | 1 |
| Bessa, J | 1 |
| Winkle, J | 1 |
| Doukas, D | 1 |
| Kay, LJ | 1 |
| Sousa, N | 1 |
| Dulawa, SM | 1 |
| Warden, D | 5 |
| Trivedi, MH | 9 |
| Carmody, T | 1 |
| Toups, M | 1 |
| Zisook, S | 4 |
| Lesser, I | 1 |
| Myers, A | 1 |
| Kurian, KR | 1 |
| Morris, D | 1 |
| Rush, AJ | 9 |
| Lason-Tyburkiewicz, M | 1 |
| Litwa, E | 1 |
| Willner, P | 1 |
| Benatti, C | 1 |
| Alboni, S | 1 |
| Blom, JM | 1 |
| Gandolfi, F | 1 |
| Mendlewicz, J | 1 |
| Brunello, N | 1 |
| Tascedda, F | 1 |
| Zhang, Y | 1 |
| Wang, Y | 1 |
| Wang, L | 1 |
| Bai, M | 1 |
| Zhang, X | 1 |
| Zhu, X | 1 |
| Li, XL | 1 |
| Yuan, YG | 1 |
| Xu, H | 1 |
| Wu, D | 1 |
| Geng, LY | 1 |
| Wu, FF | 1 |
| Tang, H | 1 |
| Xu, L | 1 |
| Schmidt, P | 1 |
| Brakemeier, EL | 1 |
| Ide, S | 1 |
| Satoyoshi, H | 1 |
| Minami, M | 1 |
| Satoh, M | 1 |
| Zhitkova, JV | 1 |
| Gourab, K | 1 |
| Schmit, BD | 1 |
| Hornby, TG | 1 |
| Angermann, CE | 1 |
| Gelbrich, G | 1 |
| Störk, S | 1 |
| Gunold, H | 1 |
| Edelmann, F | 1 |
| Wachter, R | 1 |
| Schunkert, H | 1 |
| Graf, T | 1 |
| Kindermann, I | 1 |
| Haass, M | 1 |
| Blankenberg, S | 1 |
| Pankuweit, S | 1 |
| Prettin, C | 1 |
| Gottwik, M | 1 |
| Böhm, M | 1 |
| Faller, H | 1 |
| Deckert, J | 1 |
| Ertl, G | 1 |
| Jiang, H | 1 |
| Li, X | 1 |
| Chen, S | 1 |
| Lu, N | 1 |
| Yue, Y | 1 |
| Liang, J | 1 |
| Zhang, Z | 1 |
| Yuan, Y | 1 |
| Sanna, MD | 1 |
| Ghelardini, C | 1 |
| Galeotti, N | 1 |
| Lapiz-Bluhm, MD | 2 |
| Soto-Piña, AE | 1 |
| Hensler, JG | 1 |
| Morilak, DA | 2 |
| Gilmer, WS | 2 |
| Gollan, JK | 1 |
| Wisniewski, SR | 8 |
| Howland, RH | 3 |
| Miyahara, S | 2 |
| Fleck, J | 1 |
| Thase, ME | 3 |
| Alpert, JE | 1 |
| Nierenberg, AA | 6 |
| Fava, M | 7 |
| Lekakis, J | 1 |
| Ikonomidis, I | 1 |
| Papoutsi, Z | 1 |
| Moutsatsou, P | 1 |
| Nikolaou, M | 1 |
| Parissis, J | 1 |
| Kremastinos, DT | 1 |
| McGrath, PJ | 3 |
| Khan, AY | 1 |
| Stewart, JW | 2 |
| Morris, DW | 2 |
| Karlsson, H | 1 |
| Schulte-Herbrüggen, O | 1 |
| Fuchs, E | 1 |
| Abumaria, N | 2 |
| Ziegler, A | 1 |
| Danker-Hopfe, H | 1 |
| Hiemke, C | 2 |
| Hellweg, R | 1 |
| Pollack, MH | 1 |
| Klein, DN | 1 |
| Arnow, BA | 1 |
| Barkin, JL | 1 |
| Dowling, F | 1 |
| Kocsis, JH | 1 |
| Leon, AC | 1 |
| Manber, R | 1 |
| Rothbaum, BO | 1 |
| Masand, P | 1 |
| Narasimhan, M | 1 |
| Romano-Torres, M | 1 |
| Fernández-Guasti, A | 1 |
| Mazza, M | 1 |
| Mazza, O | 1 |
| Pazzaglia, C | 1 |
| Padua, L | 1 |
| Mazza, S | 1 |
| Iancu, I | 1 |
| Tschernihovsky, E | 1 |
| Bodner, E | 1 |
| Piconne, AS | 1 |
| Lowengrub, K | 1 |
| Berger, W | 1 |
| Mehra, A | 1 |
| Lenoci, M | 1 |
| Metzler, TJ | 1 |
| Otte, C | 1 |
| Tarasovsky, G | 1 |
| Mellon, SH | 1 |
| Wolkowitz, OM | 1 |
| Marmar, CR | 1 |
| Neylan, TC | 1 |
| Milinevskiĭ, IV | 1 |
| Shabaldina, EV | 1 |
| Shamova, IP | 1 |
| Shabaldin, AV | 1 |
| Wang, J | 1 |
| Liu, X | 1 |
| Mullins, CD | 1 |
| Furr, A | 1 |
| Sung, SC | 2 |
| Haley, CL | 2 |
| Chan, HN | 1 |
| Balasubramani, GK | 3 |
| Gaynes, BN | 2 |
| Hollon, SD | 1 |
| Chen, YC | 1 |
| Tan, QR | 1 |
| Dang, W | 1 |
| Wang, HN | 1 |
| Zhang, RB | 1 |
| Li, ZY | 1 |
| Lin, H | 1 |
| Liu, R | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Araya-Callís, C | 1 |
| Flugge, G | 1 |
| Kurian, BT | 1 |
| Bose, A | 2 |
| Heydorn, WE | 1 |
| Marcos, E | 1 |
| Adnot, S | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 1 |
| Hamon, M | 1 |
| Eddahibi, S | 1 |
| Hartz, AJ | 1 |
| Bentler, SE | 1 |
| Brake, KA | 1 |
| Kelly, MW | 1 |
| Lavretsky, H | 1 |
| Kim, MD | 1 |
| Kumar, A | 1 |
| Reynolds, CF | 1 |
| Lavori, PW | 1 |
| Sackeim, HA | 1 |
| Quitkin, FM | 1 |
| Kashner, TM | 1 |
| Kupfer, DJ | 1 |
| Rosenbaum, JF | 1 |
| Alpert, J | 1 |
| Biggs, MM | 2 |
| Shores-Wilson, K | 2 |
| Lebowitz, BD | 1 |
| Ritz, L | 2 |
| Niederehe, G | 1 |
| Ashina, S | 1 |
| Bendtsen, L | 2 |
| Jensen, R | 2 |
| Tucker, P | 1 |
| Ruwe, WD | 1 |
| Masters, B | 1 |
| Parker, DE | 1 |
| Hossain, A | 1 |
| Trautman, RP | 1 |
| Wyatt, DB | 1 |
| Bomholt, SF | 1 |
| Mikkelsen, JD | 1 |
| Blackburn-Munro, G | 1 |
| Fontenelle, LF | 1 |
| Mendlowicz, MV | 1 |
| Miguel, EC | 1 |
| Versiani, M | 1 |
| Norquist, G | 1 |
| Lebowitz, B | 1 |
| Voon, V | 1 |
| Lang, AE | 1 |
| Davidson, JR | 1 |
| Wang, Q | 1 |
| Strekalova, T | 1 |
| Gorenkova, N | 1 |
| Schunk, E | 1 |
| Dolgov, O | 1 |
| Bartsch, D | 1 |
| Becker, ME | 1 |
| Hertzberg, MA | 1 |
| Moore, SD | 1 |
| Dennis, MF | 1 |
| Bukenya, DS | 1 |
| Beckham, JC | 1 |
| Jerome, L | 1 |
| Boz, C | 1 |
| Gazioglu, S | 1 |
| Altunayoglu, V | 1 |
| Hocaoglu, C | 1 |
| Montross, L | 1 |
| Kasckow, J | 1 |
| Mohamed, S | 1 |
| Palmer, BW | 1 |
| Patterson, TL | 1 |
| Golshan, S | 1 |
| Fellows, I | 1 |
| Lehman, D | 1 |
| Solorzano, E | 1 |
| Wang, SH | 1 |
| Guo, YJ | 1 |
| Teng, GJ | 1 |
| Chen, BA | 1 |
| Sarkar, R | 1 |
| Klein, J | 1 |
| Krüger, S | 1 |
| Iskedjian, M | 1 |
| Walker, JH | 1 |
| Bereza, BG | 1 |
| Le Melledo, JM | 1 |
| Einarson, TR | 1 |
| Brown, CS | 1 |
| Franks, AS | 1 |
| Wan, J | 1 |
| Ling, FW | 1 |
| Olesen, J | 1 |
| Salokangas, RK | 2 |
| Saarijärvi, S | 2 |
| Taiminen, T | 1 |
| Kallioniemi, H | 1 |
| Lehto, H | 2 |
| Niemi, H | 2 |
| Tuominen, J | 1 |
| Ahola, V | 2 |
| Syvälahti, E | 2 |
| Taiminen, TJ | 1 |
| Baraczka, K | 1 |
| Jankó, Z | 1 |
| Vargha, K | 1 |
| Márkus, H | 1 |
| Apelqvist, G | 1 |
| Wikell, C | 1 |
| Hindfelt, B | 1 |
| Bergqvist, PB | 1 |
| Andersson, G | 1 |
| Bengtsson, F | 1 |
| Sánchez, C | 2 |
| Iakovlev, VA | 1 |
| Belinskiĭ, AV | 1 |
| Dorovskikh, IV | 1 |
| Nalepa, I | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Larsen, JJ | 1 |
| Arnt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Enhanced Motor Recovery Using Serotonergic Agents in Stroke[NCT01751854] | Phase 1 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression[NCT03207438] | Phase 4 | 1,790 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults[NCT00305500] | Phase 3 | 100 participants | Interventional | 2006-03-31 | Completed | ||
| Digital Interventions as an Add-on Tool in Generalized Anxiety Disorder Treatment: A Randomized Clinical Trial[NCT05375851] | 60 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Dallas 2K: A Natural History Study of Depression[NCT02919280] | 2,000 participants (Anticipated) | Observational | 2016-09-30 | Recruiting | |||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial[NCT05008939] | 15 participants (Anticipated) | Interventional | 2021-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
Defined as a 50% score reduction from baseline. (NCT03207438)
Timeframe: Day 4 - Week 6
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Day 4 | Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 1 - Insomnia | 6 | 12 | 31 | 44 | 45 |
| Placebo 1 - No Insomnia | 0 | 1 | 1 | 8 | 5 |
| Quetiapine XR 50mg - Insomnia | 8 | 26 | 42 | 59 | 64 |
| Quetiapine XR 50mg - No Insomnia | 0 | 3 | 8 | 5 | 9 |
Calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: Day 4 - Week 6
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Day 4 | Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 1 | 6 | 11 | 28 | 49 | 51 |
| Quetiapine XR 50mg | 6 | 22 | 44 | 57 | 66 |
50% score reduction from baseline calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: 1 - 6 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 2 - Melancholic Depression | 26 | 45 | 61 | 64 |
| Placebo 2 - Nonmelancholic Depression | 46 | 100 | 136 | 176 |
| Quetiapine XR 150-300mg - Melancholic Depression | 53 | 90 | 124 | 132 |
| Quetiapine XR 150-300mg - Nonmelancholic Depression | 68 | 179 | 231 | 260 |
MADRS is the Montgomery-Asberg Depression Rating Scale. Total scores on this scale range from 0-60. However the response variable is binary coded (0 = No Response, 1 = Response). (NCT03207438)
Timeframe: 1 - 6 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 2 - Melancholic Depression | 28 | 41 | 62 | 64 |
| Placebo 2 - Nonmelancholic Depression | 47 | 100 | 136 | 174 |
| Quetiapine XR 150-300mg - Melancholic Depression | 63 | 105 | 124 | 141 |
| Quetiapine XR 150-300mg - Nonmelancholic Depression | 86 | 195 | 251 | 274 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
2 reviews available for citalopram and Chronic Disease
| Article | Year |
|---|---|
Refractory generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiet | 2009 |
Update on partial response in depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Chronic Disease; Citalopram; Comorbi | 2009 |
32 trials available for citalopram and Chronic Disease
| Article | Year |
|---|---|
The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disease; Citalopram; Co | 2017 |
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso | 2014 |
Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Chronic Major Depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder, M | 2015 |
Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke.
Topics: Aged; Ankle; Chronic Disease; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Hemiplegi | 2015 |
Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression; Dru | 2016 |
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
Topics: Adult; Aged; Aorta; Cell Adhesion; Cell Survival; Chronic Disease; Citalopram; Depression; Endotheli | 2010 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain.
Topics: Adult; Aged; Chronic Disease; Citalopram; Duloxetine Hydrochloride; Female; Health Surveys; Humans; | 2010 |
Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.
Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Human | 2010 |
Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Chronic Disease; | 2010 |
[The use of the antidepressant citalopran for the treatment of chronic pharyngitis and pharyngeal neurosis].
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Dose-Response Relation | 2011 |
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Chronic Dis | 2012 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Comorbidity; | 2012 |
Naturalistic study of the early psychiatric use of citalopram in the United States.
Topics: Chronic Disease; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Prospect | 2002 |
The effectiveness of citalopram for idiopathic chronic fatigue.
Topics: Adult; Aged; Chronic Disease; Citalopram; Drug Administration Schedule; Fatigue; Fatigue Syndrome, C | 2003 |
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants | 2003 |
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Citalopram; Clinical Protocols; Cog | 2004 |
Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Blood Platelets; Chronic Disease; Citalo | 2004 |
Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder.
Topics: Adult; Chronic Disease; Circadian Rhythm; Citalopram; Double-Blind Method; Female; Humans; Hydrocort | 2004 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; C | 2005 |
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Diagnostic and Statistical M | 2005 |
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic | 2007 |
Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache.
Topics: Adult; Character; Chronic Disease; Citalopram; Female; Fluoxetine; Harm Reduction; Humans; Internal- | 2007 |
Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia.
Topics: Age Factors; Chronic Disease; Citalopram; Comorbidity; Depression; Depressive Disorder, Major; Doubl | 2007 |
Citalopram in the treatment of women with chronic pelvic pain: an open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression | 2008 |
A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.
Topics: Adolescent; Adult; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Chronic Disease; Citalo | 1996 |
Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Citalopram; Dose-Response Relationship, Dr | 1996 |
Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia.
Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Humans; Psychiatric Status Rating Scales; S | 1997 |
[Clinical experiences with the analgesic effects of citalopram].
Topics: Analgesics; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Fibromyalgia; Hum | 1997 |
[A trial of treating depressive states with cipramil].
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder; H | 2000 |
37 other studies available for citalopram and Chronic Disease
| Article | Year |
|---|---|
Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data.
Topics: Chronic Disease; Citalopram; Depression; Depressive Disorder, Major; Humans; Recurrence; Treatment O | 2023 |
The Effect of Chronic Mild Stress and Escitalopram on the Expression and Methylation Levels of Genes Involved in the Oxidative and Nitrosative Stresses as Well as Tryptophan Catabolites Pathway in the Blood and Brain Structures.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Catalase; Chronic Disease; Citalopram; Dep | 2020 |
Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.
Topics: Alzheimer Disease; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; C | 2018 |
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP | 2019 |
The antidepressant effect of bone marrow mononuclear cell transplantation in chronic stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Marrow Transplantation; Chronic Disease; Cita | 2019 |
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Citalopram; Cycl | 2014 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram | 2014 |
Dopamine Receptor D2 and Associated microRNAs Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Corpus Striatum; Dep | 2015 |
Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats.
Topics: Animals; Antidepressive Agents; Blotting, Western; Body Weight; Brain; Chronic Disease; Citalopram; | 2015 |
Amelioration of the reduced antinociceptive effect of morphine in the unpredictable chronic mild stress model mice by noradrenalin but not serotonin reuptake inhibitors.
Topics: Analgesics; Animals; Chronic Disease; Citalopram; Disease Models, Animal; Male; Maprotiline; Mice, I | 2015 |
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti | 2015 |
Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.
Topics: Animals; Behavior, Animal; Body Weight; Case-Control Studies; Chronic Disease; Citalopram; Depressio | 2016 |
Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression.
Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; CA3 Region, Hippocampal; Ch | 2017 |
Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats.
Topics: Animals; Attention; Chronic Disease; Citalopram; Cold Temperature; Discrimination Learning; Fencloni | 2009 |
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
Topics: Adult; Chronic Disease; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistic | 2008 |
Remission in depression--is it a realistic goal?
Topics: Antidepressive Agents; Chronic Disease; Citalopram; Cognitive Behavioral Therapy; Combined Modality | 2008 |
Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress.
Topics: Adrenal Glands; Animals; Antidepressive Agents, Second-Generation; Body Weight; Brain; Brain-Derived | 2009 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi | 2009 |
Major depressive disorder and medical illness: STAR*D outcomes.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Comorbidity; Cross-Sec | 2006 |
Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.
Topics: Aging; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Conditioning, Operant; Depressio | 2010 |
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Topics: Adolescent; Adult; Algorithms; Antidepressive Agents; Chronic Disease; Citalopram; Cyclohexanols; De | 2011 |
5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Attention; beta-Cyclodextrins; Chronic Disease; Citalopr | 2012 |
The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex.
Topics: Animals; Antidepressive Agents; Behavior, Animal; beta Catenin; Blotting, Western; Chronic Disease; | 2012 |
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Astrocytes; Behavior, Animal; Chronic Disease; Ci | 2012 |
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
Topics: Acute Disease; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Chronic Disease; Citalopra | 2005 |
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cita | 2005 |
Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress.
Topics: Animals; Body Weight; Chronic Disease; Citalopram; Depression; Drinking; Hindlimb Suspension; Immers | 2006 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
Topics: Adaptation, Physiological; Adaptation, Psychological; Animals; Antidepressive Agents, Second-Generat | 2008 |
Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Citalopram; Drug Therapy, Combination; Female; | 2008 |
Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders | 2008 |
Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Chronic D | 1999 |
The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2000 |
Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model.
Topics: Animals; Cerebral Cortex; Chronic Disease; Citalopram; Disease Models, Animal; Drug Therapy, Combina | 2002 |
Reduction in locomotor activity of arthritic rats as parameter for chronic pain: effect of morphine, acetylsalicylic acid and citalopram.
Topics: Animals; Arthritis; Arthritis, Experimental; Aspirin; Chronic Disease; Citalopram; Exploratory Behav | 1985 |